A new low-cost version of Tecfidera, a widely used oral therapy for relapsing forms of multiple sclerosis (MS), is now available in the U.S. for a fraction of the typical cost. Launched by Civicascript, this generic form of dimethyl fumarate is expected to significantly improve access to…
The first person with multiple sclerosis (MS) has been successfully imaged in a clinical trial evaluating a new positron emission tomography (PET) tracer designed to detect changes in myelin loss, or demyelination. The Phase 1 study (NCT04699747), a joint effort between Quantum Biopharma and Massachusetts…
Bionxt Solutions is getting ready to launch a pilot clinical trial to test BNT23001, its sublingual (under-the-tongue) version of cladribine to treat multiple sclerosis (MS). The treatment would be an alternative to Mavenclad, the approved tablet form of cladribine. Bionxt‘s thin-film formulation quickly dissolves under the tongue,…
Early treatment with Ocrevus (ocrelizumab) may help protect the cerebellum, a region of the brain that plays a key role in motor coordination, cognitive function, and emotional regulation, from damage in people with multiple sclerosis (MS), a study suggested. Data from the clinical studies that supported Ocrevus’ approval…
Exercise programs that are culturally tailored to Hispanics with multiple sclerosis (MS) may help these patients engage in regular physical activity, according to an interview-based study. The patients surveyed also say they prefer exercise that’s performed three to five days per week, and led by a coach in community…
An online training program for managing memory and cognitive difficulties may help people with multiple sclerosis (MS), a study suggests. The program, delivered entirely through virtual sessions, taught participants practical strategies to boost memory then guided them about using the techniques in real-world situations, such as organizing errands, planning…
Rituximab, sometimes used off-label as a multiple sclerosis (MS) treatment, may be as effective — at a much lower cost to patients — as the approved therapy Ocrevus (ocrelizumab) at managing relapsing forms of the disease, a new study from Egypt suggests. The study’s results showed that the…
Sexual dysfunction affects 80% of women in Iran with multiple sclerosis (MS), with older age and lower education levels seen as key risk factors, a study found. The study, ”The prevalence of sexual dysfunction and its contributors among the women with multiple sclerosis,” was published in BMC Women’s…
Nearly 50% of people with multiple sclerosis (MS) report pronounced fatigue, which has a significantly negative effect on their well-being, a new study from Finland has found. In an analysis of data from more than 500 patients from the Finnish MS registry, individuals with self-perceived fatigue were more likely…
Starting Tysabri (natalizumab) early in multiple sclerosis (MS) treatment may lead to better outcomes, including greater reductions in relapse rates and less use of MS-related healthcare services over starting it after other therapies. That’s according to a U.S. healthcare claims analysis of more than 1,500 adults with MS.
Cognitive impairment is common in people with multiple sclerosis (MS) who have not previously received treatment, affecting about 1 in 4 patients, and rates are particularly higher in those with secondary progressive MS (SPMS), a new study found. “The current study demonstrates that a significant portion of MS…
Myrobalan Therapeutics has been awarded a grant of more than $850,000 from the National Multiple Sclerosis Society to advance its new oral candidate MRO-002 for treating progressive forms of multiple sclerosis (MS). The funding was made through the society’s Fast Forward program, which seeks to bridge the…
People with multiple sclerosis (MS) who receive anti-CD20 therapies such as Ocrevus (ocrelizumab) are significantly less likely to discontinue their treatment compared with patients who are given other disease-modifying therapies (DMTs), a Swiss study has found. Staying on treatment may be related to the effectiveness of B-cell-depleting…
Get regular updates to your inbox.
